Icotrokinra became the first approved oral IL23 receptor blocker, and a trial found tirzepatide plus ixekizumab gave deeper responses.
Recap by typeshit. Post by Samuel Hume on X.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
The telehealth company is also adding blood testing services alongside the lower costs for its compounded GLP-1 options.
Huberman says verified, US-made sourcing would change the peptide market, and wonders which compounds beyond GLPs would qualify.
A general explainer on why the body holds onto its large fat reserves even though they carry tens of thousands of calories.
The skincare brand suggests applying its peptide serum first for hydration, then retinal at night for anti-ageing.
The IMF addresses whether GLP-1 weight loss medications are a safe option for people with myeloma, including those with insulin resistance.
Loading…